Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease

NCT07901933 is registered in ClinicalTrials.gov with Cajal Therapeutics Inc. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07901933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
Lead sponsor
Cajal Therapeutics Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2027
Enrollment
24 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, chronic kidney disease

Arms

As registered; 2 arms.

  • CTX001 plus oral iron ExperimentalCTX001, Ferrous Sulfate

    Participants receive CTX001 at the assigned cohort dose together with oral iron once daily for 29 days.

  • Placebo plus oral iron Placebo comparatorFerrous Sulfate, Placebo

    Participants receive matching placebo together with oral iron once daily for 29 days.

Primary endpoints

Registered primary outcome measures; 6 primary.

  • Incidence of Treatment-Emergent Adverse Events (TEAEs) From first administration of study intervention through the end of study participation, around Day 36.

    Number and percentage of participants with at least one (TEAE). An adverse event (AE) is any untoward medical occurrence in a participant, whether or not considered related to the study intervention. An AE is considered a treatment-emergent AE (TEAE) if the AE begins or worsens after the first dose of study intervention and on or before the last study visit.

  • Incidence of Serious TEAEs From first administration of study intervention through the end of study participation, around Day 36.

    Number and percentage of participants with at least one serious treatment-emergent adverse event (TEAE). A serious AE (SAE) is defined as any AE that, at any dose, meets one or more of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital anomaly or birth defect; or any important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.

  • Incidence of Clinically Significant Changes in Physical Examination From first administration of study intervention through the end of study participation, around Day 36.

    The investigator assesses the clinical significance of changes in physical examination findings.

  • Incidence of Clinically Significant Changes in Safety Laboratory Values From first administration of study intervention through the end of study participation, around Day 36.

    Safety laboratory evaluations include blood counts, serum chemistries, coagulation studies and urinalyses. Determination of clinical significance is based on investigator discretion.

  • Incidence of Clinically Significant Changes in Vital Signs From first administration of study intervention through the end of study participation, around Day 36

    Vital signs include heart rate, respiratory rate, blood pressure, and temperature. Determination of clinical significance is based on investigator discretion.

+1 more primary endpoint

Lead sponsor's other trials

Cajal Therapeutics Inc., most recent start first.

Similar trials

Same condition (Anemia) and phase, most recent start first.